The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Understanding the pathology and mechanisms of type I diabetic bone loss
Abstract
Type I (T1) diabetes, also called insulin dependent diabetes mellitus (IDDM), is characterized by little or no insulin production and hyperglycemia. One of the less well known complications of T1‐diabetes is bone loss which occurs in humans and animal models. This complication is receiving increased attention because T1‐diabetics are living longer due to better therapeutics, and are faced with their existing health concerns being compounded by complications associated with aging, such as osteoporosis. Both male and female, endochondrial and intra‐membranous, and axial and appendicular bones are susceptible to T1‐diabetic bone loss. Exact mechanisms accounting for T1‐diabetic bone loss are not known. Existing data indicate that the bone defect in T1‐diabetes is anabolic rather than catabolic, suggesting that anabolic therapeutics may be more effective in preventing bone loss. Potential contributors to T1‐diabetic suppression of bone formation are discussed in this review and include: increased marrow adiposity, hyperlipidemia, reduced insulin signaling, hyperglycemia, inflammation, altered adipokine and endocrine factors, increased cell death, and altered metabolism. Differences between T1‐diabetic‐ and age‐associated bone loss underlie the importance of condition specific, individualized treatments for osteoporosis. Optimizing therapies that prevent bone loss or restore bone density will allow T1‐diabetic patients to live longer with strong healthy bones. J. Cell. Biochem. 102: 1343–1357, 2007. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endocrine regulation of energy metabolism by the skeleton
Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.05.047 · Cited by 2,554
Kato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B. H.-J., Glass, D. A., Hartmann, C., Li, L., Hwang, T.-H., Brayton, C. F., et al. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200201089 · Cited by 1,086 · cited 1×
“…metabolic stress, and wnt signaling are thought to contribute to the regulation of osteoblast versus adipocyte lineage selection [Thomas et al., 1999; Kato et al., 2002; Little et al., 2002; Cheng et al., 2003; Bennett et al., 2005; Hong et al., 2005; Kindblom et al., 2005; Irwin et al., 2007].”
BackgroundHamrick, M. W., Della-Fera, M. A., Choi, Y.-H., Pennington, C., Hartzell, D., & Baile, C. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050103 · Cited by 268 · cited 1×
“While not as effective in leptin-replete mice, leptin treatment can be an effective therapeutic to increase bone density in leptin-deficient mice [Hamrick et al., 2005] and in hind limb suspended mice [Martin et al., 2005].”
Background
Cited by
Marrow Fat and Bone—New Perspectives
Fazeli, P. K., Horowitz, M. C., MacDougald, O. A., Scheller, E. L., Rodeheffer, M. S., Rosen, C. J., & Klibanski, A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3634 · Cited by 416
McCabe, L. R., Irwin, R., Schaefer, L., & Britton, R. A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24340 · Cited by 273
Self-citationCirculating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., Capodarca, C., Franci, M. B., Campagna, M. S., Calabrò, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2958 · Cited by 272
The bone–fat interface: basic and clinical implications of marrow adiposity
Devlin, M. J., & Rosen, C. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70007-5 · Cited by 255
Metadata
- Authors
- McCabe, L. R.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2007-11
- Volume
- 102
- Issue
- 6
- Pages
- 1343-1357
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W1997515464
- Cited by
- 226
- References
- 3
- FWCI
- 12.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.